OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Comparative renal outcomes of matched cohorts of patients with type 2 diabetes receiving SGLT2 inhibitors or GLP-1 receptor agonists under routine care
Gian Paolo Fadini, Enrico Longato, Mario Luca Morieri, et al.
Diabetologia (2024) Vol. 67, Iss. 11, pp. 2585-2597
Open Access | Times Cited: 6
Gian Paolo Fadini, Enrico Longato, Mario Luca Morieri, et al.
Diabetologia (2024) Vol. 67, Iss. 11, pp. 2585-2597
Open Access | Times Cited: 6
Showing 6 citing articles:
SGLT2-Inhibitoren und GLP-1-Rezeptoragonisten im direkten Vergleich
Diabetologie und Stoffwechsel (2025) Vol. 20, Iss. 02, pp. 93-93
Closed Access
Diabetologie und Stoffwechsel (2025) Vol. 20, Iss. 02, pp. 93-93
Closed Access
Inkretine für CKD-Patienten
Leonie Kraft, Jörg Latus, Moritz Schanz
Deleted Journal (2025)
Closed Access
Leonie Kraft, Jörg Latus, Moritz Schanz
Deleted Journal (2025)
Closed Access
Néphroprotection et diabète de type 2 : regards croisés en 2025 sur quatre (nouvelles) classes thérapeutiques d’intérêt
Martin Buysschaert, J. Abodo, Jamal Belkhadir, et al.
Médecine des Maladies Métaboliques (2025)
Closed Access
Martin Buysschaert, J. Abodo, Jamal Belkhadir, et al.
Médecine des Maladies Métaboliques (2025)
Closed Access
Cardiovascular and renal effects of the combination therapy of a GLP-1 receptor agonist and an SGLT2 inhibitor in observational real-life studies
André Scheen
Diabetes & Metabolism (2024), pp. 101594-101594
Closed Access | Times Cited: 2
André Scheen
Diabetes & Metabolism (2024), pp. 101594-101594
Closed Access | Times Cited: 2
GLP-1 receptor agonists: new kids in the block of renoprotection for people with type 2 diabetes and chronic kidney disease
Theocharis Koufakis, Djordje S. Popovic, Paschalis Karakasis, et al.
Expert Opinion on Pharmacotherapy (2024) Vol. 25, Iss. 15, pp. 1979-1982
Closed Access
Theocharis Koufakis, Djordje S. Popovic, Paschalis Karakasis, et al.
Expert Opinion on Pharmacotherapy (2024) Vol. 25, Iss. 15, pp. 1979-1982
Closed Access
Nierenschutz von unterschiedlichen Seiten
Thomas M. Heim
Info Diabetologie (2024) Vol. 18, Iss. 5, pp. 42-42
Closed Access
Thomas M. Heim
Info Diabetologie (2024) Vol. 18, Iss. 5, pp. 42-42
Closed Access
The use of SGLT2 inhibitors and GLP-1 receptor agonists in older patients: a debate on approaches in CKD and non-CKD populations
Sophie Liabeuf, Roberto Minutolo, Jürgen Floege, et al.
Clinical Kidney Journal (2024) Vol. 18, Iss. 2
Open Access
Sophie Liabeuf, Roberto Minutolo, Jürgen Floege, et al.
Clinical Kidney Journal (2024) Vol. 18, Iss. 2
Open Access
